Efgartigimod for IVIG-dependent myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests a medication called efgartigimod for people with myasthenia gravis who need regular IVIG treatments. The goal is to see if efgartigimod can help reduce the need for IVIG.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a positive antibody test for myasthenia gravis (AChR antibodies).
- You have been on regular IVIG treatments for at least one year with a stable dose and no major changes in your condition for the past 4 months.
- You haven't changed or added certain medications (called NSISTs) in the last 6 months or steroids in the last 3 months.
- You cannot have had rituximab, eculizumab, or plasma exchange in the last 6 months, or a thymectomy in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a follow-up treatment with ublituximab (given as an infusion) can help myasthenia gravis patients who first received efgartigimod. The goal is to see if it provides lasting control of MG symptoms.
This study tests a drug called efgartigimod (given through an IV) to see if it can help people who are in a myasthenic crisis — a severe flare-up of myasthenia gravis that makes it hard to breathe. The goal is to help patients recover faster from this dangerous worsening of symptoms.
This trial studies how efgartigimod (given through a vein) behaves in children and whether it is safe and effective for generalized myasthenia gravis. It is designed for children who have not done well enough with standard treatments like steroids or other immune medicines.
This study tests a new treatment called efgartigimod for people who have been recently diagnosed with generalized myasthenia gravis (gMG). It aims to see if this medicine can help manage symptoms like muscle weakness.
This study tests an investigational drug called efgartigimod for children and teens with generalized myasthenia gravis. It may help those who haven't responded well enough to standard treatments.
This study follows people with generalized myasthenia gravis (a condition causing muscle weakness) who are already starting a medicine called efgartigimod as part of their regular care. Researchers want to understand how this treatment affects your daily life and overall experience with the disease.
Hear when a new Myasthaenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.